Trials / Completed
CompletedNCT00121030
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patients With Gynecological Malignancies Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | darbepoetin alfa | |
| DRUG | recombinant human erythropoietin (rHuEPO) |
Timeline
- Start date
- 2002-10-01
- Completion
- 2003-12-01
- First posted
- 2005-07-21
- Last updated
- 2007-12-24
Source: ClinicalTrials.gov record NCT00121030. Inclusion in this directory is not an endorsement.